CN114096537B - 肉瘤治疗方法的有用组合 - Google Patents

肉瘤治疗方法的有用组合 Download PDF

Info

Publication number
CN114096537B
CN114096537B CN202080039624.8A CN202080039624A CN114096537B CN 114096537 B CN114096537 B CN 114096537B CN 202080039624 A CN202080039624 A CN 202080039624A CN 114096537 B CN114096537 B CN 114096537B
Authority
CN
China
Prior art keywords
compound
subject
sarcoma
dose
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080039624.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114096537A (zh
Inventor
M·L·威特尔
曹良弦
J·希迪
R·斯皮格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of CN114096537A publication Critical patent/CN114096537A/zh
Application granted granted Critical
Publication of CN114096537B publication Critical patent/CN114096537B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080039624.8A 2019-03-27 2020-03-27 肉瘤治疗方法的有用组合 Active CN114096537B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825017P 2019-03-27 2019-03-27
US62/825,017 2019-03-27
PCT/US2020/025532 WO2020198705A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Publications (2)

Publication Number Publication Date
CN114096537A CN114096537A (zh) 2022-02-25
CN114096537B true CN114096537B (zh) 2025-01-10

Family

ID=72609016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080039624.8A Active CN114096537B (zh) 2019-03-27 2020-03-27 肉瘤治疗方法的有用组合

Country Status (11)

Country Link
US (1) US20220152024A1 (https=)
EP (1) EP3947379A4 (https=)
JP (1) JP7602481B2 (https=)
CN (1) CN114096537B (https=)
AU (1) AU2020248103A1 (https=)
BR (1) BR112021019170A2 (https=)
CA (1) CA3134648A1 (https=)
EA (1) EA202192349A1 (https=)
IL (1) IL286647A (https=)
MX (1) MX2021011688A (https=)
WO (1) WO2020198705A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104918919A (zh) * 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (https=) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
WO2008075330A1 (en) * 2006-12-20 2008-06-26 J-C Health Care Ltd. Method for administration of pegylated liposomal doxorubicin
EP3836932A2 (en) * 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104918919A (zh) * 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂

Also Published As

Publication number Publication date
JP2022519930A (ja) 2022-03-25
IL286647A (en) 2021-10-31
JP7602481B2 (ja) 2024-12-18
AU2020248103A1 (en) 2021-10-21
EA202192349A1 (ru) 2022-02-01
CN114096537A (zh) 2022-02-25
EP3947379A4 (en) 2022-12-21
WO2020198705A1 (en) 2020-10-01
EP3947379A1 (en) 2022-02-09
MX2021011688A (es) 2022-01-24
US20220152024A1 (en) 2022-05-19
BR112021019170A2 (pt) 2022-03-03
CA3134648A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
EP3923941B1 (en) Pharmaceutical combination comprising tno155 and ribociclib
US20240108618A1 (en) Kras g12c inhibitor dosing regimens
RU2665949C2 (ru) Селективность в отношении мутантных форм и комбинации соединения, представляющего собой ингибитор фосфоинозитид-3-киназы, и химиотерапевтических агентов для лечения рака
US20200352905A1 (en) 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
KR20230031242A (ko) 골수증식성 신생물의 치료를 위한 병용 요법
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
US8501792B2 (en) Treating cancer with desthiazolyl ritonavir
CN114096537B (zh) 肉瘤治疗方法的有用组合
CN113227138A (zh) IL-1β结合抗体的用途
CN120752053A (zh) 含抗tim-3抗体的药物组合
EA046841B1 (ru) Комбинации, пригодные в способе лечения саркомы
RU2812782C2 (ru) Способ лечения острого миелоидного лейкоза
AU2020209767B2 (en) Method for treating an acute myeloid leukemia
US20220143016A1 (en) Method for treating a multiple myeloma
CN120569198A (zh) 一种内磺酰胺化合物治疗胆道癌的用途
EA047152B1 (ru) Способ лечения множественной миеломы
EA053195B1 (ru) Ингибитор kras g12c для лечения рака
HK40093427A (en) Drug for treating tumor
HK40012625A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP3246029A1 (en) Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant